AI Deployment Governance in African Health Systems

This SME-tier course equips specialists, informaticists, and clinical leaders to evaluate, validate, and safely deploy artificial intelligence in African health systems, neither dismissing the technology as hype nor adopting it on faith. Over six weeks (12 CEU contact hours), you will learn to grade an AI application by maturity and evidence, from WHO-recommended TB CAD to early-stage generative tools, and recommend a deployment stance proportionate to that evidence. You will apply a WHO-aligned deployment checklist covering intended use, local validation, clinical governance, explainability, audit logging, equity monitoring, and an accountable institution to real continental cases.

You will design augmentation architecture in which AI serves as triage and second reader under clinical governance, distinguish the SaMD and LLM/LMM governance pathways, govern the conversational and generative frontier against fabrication, bias, and over-reliance, and diagnose algorithmic bias in cross-continental AI transfer. It is built for clinical leaders making AI deployment defensible and equitable.

Course glossary

• Algorithmic bias — Systematic, differential error in an AI model arising from unrepresentative or skewed training data, often acting invisibly through proxies rather than explicit variables.
• Artificial intelligence (AI) — Computer systems performing tasks that normally require human intelligence (image interpretation, prediction, language understanding); in health, deployed under clinical governance for triage, screening, and decision support.
• Augmentation architecture — Designing AI as triage and second reader within clinical governance, with escalation to humans, audit trails, and a workforce trained to supervise it.
• Automation over-reliance — The human tendency to defer to an AI's fluent output even when it is wrong; intensified for overloaded users and authoritative-sounding models.
• Bias audit — A structured evaluation of a model's performance across subgroups, made a regulatory requirement alongside post-deployment equity monitoring.
• Clinical decision support system (CDSS) — Software providing health workers with knowledge and patient-specific guidance (protocols, alerts, risk scores) at the point of care.
• Computer-aided detection (CAD) — AI software that reads medical images to detect or triage disease; the TB chest-X-ray use case is WHO-recommended.
• Confirmation chain — The sequence of confirmatory testing, treatment, and follow-up that must follow a positive AI screen for the tool to deliver clinical value.
• Critical supervision — The workforce competency of overseeing algorithmic outputs: understanding intended use and limits, spotting implausible results, and escalating appropriately.
• Deployment checklist (WHO-aligned) — Intended use, local validation, clinical governance/escalation, explainability, audit logging, equity monitoring, and an accountable institution.
• Deployment stance — The governance posture (scale / pilot-with-validation / integrate / contain) appropriate to an application's evidence posture.
• Equity monitoring — Ongoing post-deployment tracking of AI performance across subgroups to detect differential failure that pre-deployment validation can miss.
• Explainability — The property of an AI output being interpretable to the users who must act on it, calibrated to their role.
• Fabrication (hallucination) — An LLM's production of fluent, confident, but false content; clinically dangerous because its authoritative tone invites trust.
• Generative documentation — AI drafting of notes, letters, and reports; lowest-risk conversational use when human review is mandatory and the clinician remains author of record.
• Intended use — The precise, documented statement of what an AI tool is for, on whom, and for which decision; using a tool outside its intended use renders it unvalidated.
• Large language model (LLM) / large multi-modal model (LMM) — AI systems that generate language (and, for LMMs, process other modalities), enabling conversational assistants and client triage.
• Leapfrogging — Skipping legacy stages of technological development; in African health, the cognitive "second leapfrog" of AI- and data-extended capability.
• Local validation — Confirming an AI tool performs acceptably on the local population, equipment, and subgroups before clinical deployment; mandatory for any imported model.
• Post-market surveillance — Ongoing monitoring of a tool's real-world performance after regulatory approval, the regulatory counterpart to the checklist's equity monitoring.
• Proxy bias — Bias introduced when a model predicts a target via a correlated but skewed stand-in (e.g., cost as a proxy for need), as in the Obermeyer study.
• SaMD pathway — The medical-device regulatory route applied to AI: risk classification, performance evidence for intended use, change control, and post-market surveillance.
• SMART guidelines — WHO's machine-readable clinical recommendations, enabling national protocol updates to deploy at software speed rather than retraining speed.
• Software as a Medical Device (SaMD) — Software intended for a medical purpose that functions without being part of a hardware device; the regulatory category many health AI tools fall under.
• WHO LMM guidance — WHO's 2024 guidance on large multi-modal models, cataloguing the fabrication, bias, and over-reliance failure modes and prescribing governed deployment.

---

Frequently asked questions

Q: Is AI in African health systems ready for real use, or is it mostly hype? A: Both statements are true of different applications, which is exactly why you must grade AI by maturity rather than judge "AI" as one thing. TB computer-aided detection (CAD) is WHO-recommended and ready to deploy under governance; SMART-guideline decision support is a mature pathway to integrate; screening tools (retinopathy, cervix, skin) have strong external trials but need local validation; conversational and generative AI are promising but early and must be confined to governed, supervised pilots. The discipline of the course is to match the deployment stance to each application's evidence posture.

Q: Why is "augmentation, not replacement" the right frame for African AI? A: Because the rich-world debate about AI displacing professionals does not map onto a continent where the baseline is often one radiologist for millions. Where the workforce does not exist to be displaced, AI is capacity that otherwise would not exist — it is workforce. The correct design is augmentation architecture: AI as triage and second reader under clinical governance, with escalation to humans, audit trails, and a workforce trained in the critical supervision of algorithmic colleagues.

Q: What exactly is on the WHO-aligned AI deployment checklist? A: Seven items: defined intended use; local validation evidence; clinical governance and escalation; explainability appropriate to users; audit logging; equity monitoring; and a responsible institution answerable when the algorithm errs. A proposal that cannot complete this checklist is not ready for clinical use, however impressive the underlying algorithm. The checklist — not the model — is what makes a deployment defensible to regulators, patients, and auditors.

Q: How do SaMD and LLM governance differ, and which applies to my tool? A: Narrow, fixed-function image/signal tools (TB CAD, retinopathy screening) fit the Software as a Medical Device pathway cleanly — risk classification, performance evidence, change control, post-market surveillance. Generative and conversational tools break SaMD's assumptions of fixed intended use and deterministic behaviour, so they need SaMD logic plus an LLM overlay: bounded scope, fabrication and bias monitoring, mandatory human review, and strong-oversight confinement. In Africa, a regulator's approval (often foreign) is necessary but never sufficient — local validation, an accountable African institution, and equity monitoring are always also required.

Q: How serious is algorithmic bias for imported models, and what do we do about it? A: It is the central equity risk, and it is structural: Africa is underrepresented in the world's health datasets, so models trained elsewhere can fail silently and differentially on African populations. The Obermeyer study shows bias entering invisibly through a biased proxy even with no race variable — a warning that multiplies in cross-continental transfer. The countermeasures are concrete and should be regulatory: mandatory local validation before clinical deployment, bias audits and post-deployment equity monitoring, representative African datasets built under African governance, and investment in African AI research capacity so models are built from African data, not merely tested on it.

Q: What is the safest way to pilot a conversational or generative AI tool? A: Match the pilot to the risk. Generative documentation is most tractable: the model drafts, the clinician reviews and signs, both versions are logged, and introduced error rates are measured. Worker assistants must be bounded — defined scope, sources surfaced, clinician review throughout the pilot. Client-facing triage chatbots are highest-risk: confine them to general health information, build prominent escalation to human care, never present output as diagnosis, and run only where a real human safety net exists. Across all three, "pilot where oversight is strong" is the operative rule.